ACE and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Some groups have suggested that earlier initiation of beta blockers and angiotensin converting enzyme inhibitors (ACEIs) in patients with myocardial dysfunction secondary to dystrophinopathies may delay the progression of cardiac dysfunction before LVEF is reduced [26, 27].